Literature DB >> 9252466

Upregulation of COX-2 in cerebral microvascular endothelial cells by smooth muscle cell signals.

H Parfenova1, T H Eidson, C W Leffler.   

Abstract

Cyclooxygenase (COX) isoform expression, intracellular localization, and function in endothelial cells from the newborn pig cerebral microvessels were investigated using COX-1- and COX-2-specific antibodies and the COX-2 inhibitor NS-398. Cerebral microvessels, microvascular endothelium, and cultured endothelial cells constitutively express both COX-1 and COX-2. NS-398 inhibits 70-90% of endothelial prostanoid production. Endothelial cells grown in noncontact coculture with smooth muscle cells for 24-48 h demonstrate a stable induction of COX-2 protein and an NS-398-sensitive increase in prostanoid synthesis. The induction of endothelial COX in mixed cell coculture is accompanied by intracellular redistribution of COX-2. In cocultured endothelial cells, COX-2 is observed in the nucleus, nuclear envelope, and cytoplasm, compared with the mainly intranuclear localization of COX-2 in cells cultured separately. No changes were observed in COX-1 protein, localized in endothelial cell cytoplasm and the nuclear envelope. These results indicate that smooth muscle cells may modify endothelial function by upregulating COX-2, which is a major functional COX isoform in cerebral microvascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252466     DOI: 10.1152/ajpcell.1997.273.1.C277

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.

Authors:  G E Serrano; N Lelutiu; A Rojas; S Cochi; R Shaw; C D Makinson; D Wang; G A FitzGerald; R Dingledine
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

2.  Arachidonic acid- and prostaglandin E2-induced cerebral vasodilation is mediated by carbon monoxide, independent of reactive oxygen species in piglets.

Authors:  Alie Kanu; Charles W Leffler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-07       Impact factor: 4.733

3.  Cyclooxygenase products stimulate carbon monoxide production by piglet cerebral microvessels.

Authors:  Alie Kanu; David Gilpin; Alexander L Fedinec; Charles W Leffler
Journal:  Exp Biol Med (Maywood)       Date:  2006-02

Review 4.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

5.  PACAP and VIP differentially preserve neurovascular reactivity after global cerebral ischemia in newborn pigs.

Authors:  Laura Lenti; Aliz Zimmermann; Dávid Kis; Orsolya Oláh; Gábor K Tóth; Orsolya Hegyi; David W Busija; Ferenc Bari; Ferenc Domoki
Journal:  Brain Res       Date:  2009-06-16       Impact factor: 3.252

6.  Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs.

Authors:  Daniel E Westholm; David D Stenehjem; Jon N Rumbley; Lester R Drewes; Grant W Anderson
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

7.  Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the Translational Silencer, T-cell Intracellular Antigen-1.

Authors:  Yifan Gong; James A Hewett
Journal:  Neuroscience       Date:  2018-01-11       Impact factor: 3.590

8.  The cold receptor TRPM8 activation leads to attenuation of endothelium-dependent cerebral vascular functions during head cooling.

Authors:  Alex L Fedinec; Jianxiong Liu; Rong Zhang; Mimily Harsono; Massroor Pourcyrous; Helena Parfenova
Journal:  J Cereb Blood Flow Metab       Date:  2021-05-20       Impact factor: 6.200

9.  Puerarin attenuates cerebral damage by improving cerebral microcirculation in spontaneously hypertensive rats.

Authors:  Xu-Dong Wu; Chen Wang; Zhen-Ying Zhang; Yan Fu; Feng-Ying Liu; Xiu-Hua Liu
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-13       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.